Cost of prescription medicines could rise under new NAFTA

The intellectual-property provisions included in the final agreement could delay when cost-saving generic and biosimilar medicines can enter the Canadian market, writes the president of the Canadian Generic Pharmaceutical Association.

Health Minister Ginette Petitpas Taylor’s mandate in large part is focused on improving access to necessary prescription medication and reduce the cost Canadian governments pay for these drugs, writes the president of the Canadian Generic Pharmaceutical Association. The Hill Times file photograph by Andrew Meade

Opinion

BY Jim Keon

September 19, 2018

Access to affordable prescription medicines is a high priority for Canadians. Health Minister Ginette Petitpas Taylor’s mandate in large part is focused on improving access to necessary prescription medication and reduce the cos...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Weekend Point of View Newsletter

A round up of the past weekâ€™s opinion writers and columnists on Saturdays and Sundays.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy